Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2013

01-06-2013 | Editorial

The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease

Authors: Puneet Puri, Arun J. Sanyal

Published in: Hepatology International | Issue 2/2013

Login to get access

Excerpt

Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health problem together with the obesity and diabetes epidemic. Currently, the spectrum of NAFLD is defined histologically as nonalcoholic fatty liver alone or simple steatosis (NAFL or SS) and nonalcoholic steatohepatitis (NASH) with or without fibrosis. Histologic details about steatosis and inflammation, cytologic ballooning, and Mallory-Denk bodies help characterize the disease spectrum. However, a noninvasive alternative to histology is presently unavailable and is an area of active investigation. …
Literature
1.
Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263.CrossRef
2.
Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–1756.CrossRef
3.
Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465–475.CrossRef
4.
Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol. 2009;158:155–163.CrossRef
5.
Ng LG, Mackay CR, Mackay F. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol. 2005;42:763–772.CrossRef
6.
Morimoto S, Nakano S, Watanabe T, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology. 2007;46:1083–1086.CrossRef
7.
Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–264.CrossRef
8.
Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467–496.CrossRef
9.
Sutherland AP, Ng LG, Fletcher CA, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174:5537–5544.CrossRef
10.
Alexaki VI, Notas G, Pelekanou V, et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol. 2009;183:5948–5956.CrossRef
11.
Hamada M, Abe M, Miyake T, et al. B cell-activating factor controls the production of adipokines and induces insulin resistance. Obesity (Silver Spring). 2011;19:1915–1922.CrossRef
12.
Kim YH, Choi BH, Cheon HG, Do MS. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp Mol Med. 2009;41:208–216.CrossRef
13.
Pelekanou V, Kampa M, Kafousi M, et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer. 2008;8:76.CrossRef
14.
Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006;27:134–139.CrossRef
15.
Migita K, Ilyassova B, Kovzel EF, et al. Serum BAFF and APRIL levels in patients with PBC. Clin Immunol. 2010;134:217–225.CrossRef
16.
Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol. 2007;68:586–591.CrossRef
17.
Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol. 2006;23:149–160.CrossRef
18.
Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol. 2000;32:689–702.CrossRef
19.
Omary MB, Ku NO. Intermediate filament proteins of the liver: emerging disease association and functions. Hepatology. 1997;25:1043–1048.CrossRef
20.
Omary MB, Ku NO, Toivola DM. Keratins: guardians of the liver. Hepatology. 2002;35:251–257.CrossRef
21.
Zatloukal K, Stumptner C, Fuchsbichler A, et al. The keratin cytoskeleton in liver diseases. J Pathol. 2004;204:367–376.CrossRef
22.
Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011;54:1224–1229.CrossRef
23.
Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.CrossRef
24.
Vincent FB, Morand EF, Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol. 2012;90:293–303.CrossRef
Metadata
Title
The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease
Authors
Puneet Puri
Arun J. Sanyal
Publication date
01-06-2013
Publisher
Springer India
Published in
Hepatology International / Issue 2/2013
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-012-9418-8

Other articles of this Issue 2/2013

Hepatology International 2/2013 Go to the issue

Original Article

Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

Original Article

B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease

Original Article

The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients

Original Article

High alanine aminotransferase level as a predictor for the incidence of macrovascular disease in type 2 diabetic patients with fatty liver disease

Original Article

Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype

Editorial

Noncirrhotic portal fibrosis: a rare cause of end-stage liver disease requiring liver transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits